FN2 Earnings Intelligence
Jazz Pharmaceuticals plc financials
Jazz Pharmaceuticals plc (JAZZ) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $591.4 | $881.5 | $1,506.3 | $2,412.9 | $1,391.9 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $3,094.2 | $3,659.4 | $3,834.2 | $4,069 | $4,267.6 |
| % Growth | 30.9% | 18.3% | 4.8% | 6.1% | 4.9% |
| Gross Profit | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| EBITDA | $197 | -$35.2 | $609 | $749.4 | -$388.6 |
| % Margin | 6.4% | -1.0% | 15.9% | 18.4% | -9.1% |
| Net Income | -$329.7 | -$224.1 | $414.8 | $560.1 | -$356.1 |
| % Margin | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
| Diluted EPS | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
| % Growth | -230.8% | 35.1% | 270.4% | 41.8% | -167.5% |
| Operating Cash Flow | $778.5 | $1,272 | $1,092 | $1,395.9 | $1,355.8 |
| CapEx | $27.6 | $29 | $24 | $38.1 | $58.8 |
| Free Cash Flow | $750.9 | $1,242.9 | $1,068 | $1,357.8 | $1,297 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $3,094.2 | $3,659.4 | $3,834.2 | $4,069 | $4,267.6 |
| Gross Profit | - | - | - | - | - |
| EBITDA | $197 | -$35.2 | $609 | $749.4 | -$388.6 |
| Net Income | -$329.7 | -$224.1 | $414.8 | $560.1 | -$356.1 |
| Diluted EPS | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $591.4 | $881.5 | $1,506.3 | $2,412.9 | $1,391.9 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $6,018.9 | $5,693.3 | $5,108 | $6,077.6 | $4,328.4 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $778.5 | $1,272 | $1,092 | $1,395.9 | $1,355.8 |
| Capital Expenditure | $27.6 | $29 | $24 | $38.1 | $58.8 |
| Free Cash Flow | $750.9 | $1,242.9 | $1,068 | $1,357.8 | $1,297 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 30.9% | 18.3% | 4.8% | 6.1% | 4.9% |
| Gross Margin | - | - | - | - | - |
| EBITDA Margin | 6.4% | -1.0% | 15.9% | 18.4% | -9.1% |
| Net Margin | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
| FCF Margin | 24.3% | 34.0% | 27.9% | 33.4% | 30.4% |
| Diluted EPS Growth | -230.8% | 35.1% | 270.4% | 41.8% | -167.5% |
Get the JAZZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.